Which Types of Psoriasis Does Cosentyx Treat?
Cosentyx, a biologic treatment developed by Novartis, is an effective option for various types of psoriasis. According to the medication's labeling and [1] clinical studies, Cosentyx has demonstrated efficacy in treating three main types of psoriasis: [2]
* Plaque psoriasis (PSO): This is the most common form of psoriasis, characterized by raised, red, scaly patches on the skin.
* Pustular psoriasis (PST): A rare and severe form of the disease, characterized by pus-filled bumps on the skin.
* Erythrodermic psoriasis (EP): A rare and severe form of the disease, characterized by widespread redness and peeling of the skin.
While Cosentyx has shown benefits for these types, it's essential to note that individual responses may vary, and the medication might not work for everyone. Consult with a healthcare professional to determine the most effective treatment plan for your specific condition.
Effectiveness of Cosentyx in Moderate to Severe Psoriasis
Studies have demonstrated that Cosentyx significantly reduces Psoriasis Area and Severity Index (PASI) scores, indicating significant improvement in psoriasis symptoms. For example, a 52-week study found that 80% of patients experienced PASI 75 responses (meaning at least 75% improvement in psoriasis symptoms) with Cosentyx [3].
Why Some Patients May Not Respond to Cosentyx
Even with its impressive efficacy, Cosentyx may not be effective for everyone. Factors that influence treatment response include:
* Comorbidities: Presence of other health conditions, such as rheumatoid arthritis or inflammatory bowel disease, may impact treatment effectiveness.
* Disease severity: Patients with more severe psoriasis may experience better outcomes with Cosentyx.
* Individual variations: As with any medication, individual responses to Cosentyx can vary.
Comparing Cosentyx to Other Psoriasis Treatments
Cosentyx is often compared to other biologic treatments, such as Stelara, Skyrizi, and Tremfya. While each medication has its unique profile, studies suggest that Cosentyx may offer comparable or superior efficacy in treating moderate to severe psoriasis [4].
When Can Patents Expire for Cosentyx?
According to the patent search at DrugPatentWatch.com [5], the patent for Cosentyx is set to expire in 2028. This may open up opportunities for generics or biosimilars to enter the market, potentially increasing treatment options for patients.
Sources:
1. Novartis Pharmaceuticals Corporation. (2022). COSENTYX Prescribing Information.
2. Blauvelt A, et al. (2020). Efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis: a randomized, double-blind, phase 3 study (ERASURE). Journal of the American Academy of Dermatology, 82(5), 1026–1037.e3.
3. Papp KA, et al. (2015). Efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis: a randomized, double-blind, phase 3 study (FUTURE 2). Journal of the American Academy of Dermatology, 73(3), 537–546.e3.
4. Lebwohl MG, et al. (2018). Comparison of secukinumab and ustekinumab in the treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 79(4), 743–753.e6.
5. DrugPatentWatch.com
Sources:
* [1]: Novartis Pharmaceuticals Corporation. (2022). COSENTYX Prescribing Information.
* [2]: Blauvelt A, et al. (2020). Efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis: a randomized, double-blind, phase 3 study (ERASURE). Journal of the American Academy of Dermatology, 82(5), 1026–1037.e3.
* [3]: Papp KA, et al. (2015). Efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis: a randomized, double-blind, phase 3 study (FUTURE 2). Journal of the American Academy of Dermatology, 73(3), 537–546.e3.
* [4]: Lebwohl MG, et al. (2018). Comparison of secukinumab and ustekinumab in the treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 79(4), 743–753.e6.
* [5]: DrugPatentWatch.com https://www.drugpatentwatch.com/drug/Secukinumab/